The India unit is currently involved in 17 clinical trials for new therapies for diseases including cancer, blood disorders, and heart diseases. While Bristol Myers' cancer cell therapies Abecma and Breyanzi have not yet been launched in India, other cancer drugs such as nivolumab and ipilimumab are sold under the brand names Opdyta and Yervoi. The company is also developing next-generation cell therapies for autoimmune diseases like multiple sclerosis, with plans to use AI to accelerate development and make these therapies more widely available, including in India.
Key takeaways:
- Bristol Myers Squibb aims to expand its research and development presence in India, with its Hyderabad facility expected to become its largest unit outside the U.S. by 2025.
- The $100-million Hyderabad facility is expected to employ over 1,500 employees and will be used to enhance drug development through digital technologies and artificial intelligence.
- The company is participating in 17 clinical trials in India for testing new therapies for cancer, blood disorders, and heart diseases.
- Bristol Myers is also developing next-generation cell therapies for autoimmune diseases such as multiple sclerosis and plans to use AI technologies to accelerate the development.